Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.67 |
| ▸ | MAPT | P10636 | 8/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.67 |
| ▸ | HPGD | P15428 | 5/20 | 0.67 |
| ▸ | LMNA | P02545 | 4/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.67 |
| ▸ | MEN1 | O00255 | 2/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.67 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.66 |
| ▸ | GLA | P06280 | 1/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.63 |
| ▸ | THRB | P10828 | 1/20 | 0.60 |
| ▸ | MAOB | P27338 | 3/20 | 0.58 |
| ▸ | MAOA | P21397 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 3/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3131662 | 0.91 | MAPT (0.62) | ALDH1A1MAPTKDM4EHPGDLMNA | |
| SCHEMBL3125211 | 0.90 | ALDH1A1 (0.63) | ALDH1A1MAPTKDM4EHPGDLMNA | |
| SCHEMBL3131560 | 0.90 | MAPT (0.61) | ALDH1A1MAPTKDM4EHPGDLMNA | |
| Hydrochloric Acid SCHEMBL3127773 | 0.90 | MAPT (0.61) | ALDH1A1MAPTKDM4EHPGDLMNA | |
| Hydrochloric Acid SCHEMBL3134221 | 0.89 | MAPT (0.60) | ALDH1A1MAPTKDM4EHPGDLMNA | |
| SCHEMBL3130403 | 0.89 | KDM4E (0.73) | ALDH1A1MAPTKDM4EHPGDLMNA | |
| SCHEMBL13757050 | 0.83 | ALDH1A1 (0.68) | ALDH1A1MAPTKDM4EHPGDLMNA | |
| SCHEMBL3134218 | 0.83 | ALDH1A1 (0.68) | ALDH1A1MAPTKDM4EHPGDLMNA | |
| SCHEMBL3124699 | 0.83 | ALDH1A1 (0.77) | ALDH1A1MAPTKDM4EHPGDLMNA | |
| SCHEMBL3124706 | 0.82 | MAPT (0.64) | ALDH1A1MAPTKDM4EHPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2021333-B1 | ANTI-PROLIFERATIVE COMPOUNDS DERIVING FROM A 3-ARYL-COUMARINE OR 3-ARYL-QUINOLIN-2-ONE AND USES THEREOF | EOS ETHICAL ONCOLOGY SCIENCE S (IT) | 2010-07-14 | — | — | EP | claimed |
| US-20090203685-A1 | ANTI-PROLIFERATIVE COMPOUNDS FROM A 3-ARYL-COUMARINE OR 3-ARYL-QUINOLIN-2-ONE AND USES THEREOF | EOS (ETHICAL ONCOLOGY SCIENCE) S.P.A. (IT) | 2009-08-13 | — | — | US | claimed |
| EP-2021333-A2 | ANTI-PROLIFERATIVE COMPOUNDS DERIVING FROM A 3-ARYL-COUMARINE OR 3-ARYL-QUINOLIN-2-ONE AND USES THEREOF | EOS - Ethical Oncology Science S.p.A. (IT) | 2009-02-11 | — | — | EP | claimed |
| WO-2007135565-A2 | ANTI-PROLIFERATIVE COMPOUNDS DERIVING FROM A 3-ARYL-COUMARINE OR 3-ARYL-QUINOLIN-2-ONE AND USES THEREOF | EOS (ETHICAL ONCOLOGY SCIENCE) S.P.A. (IT) | 2007-11-29 | — | — | WO | claimed |
| EP-1860104-A1 | Anti-proliferative compounds deriving from a 3-aryl-coumarine or 3-aryl-quinolin-2-one and uses thereof | Aptanomics (FR) | 2007-11-28 | — | — | EP | claimed |
| EP-2021333-B1 | ANTI-PROLIFERATIVE COMPOUNDS DERIVING FROM A 3-ARYL-COUMARINE OR 3-ARYL-QUINOLIN-2-ONE AND USES THEREOF | EOS ETHICAL ONCOLOGY SCIENCE S (IT) | 2010-07-14 | — | — | EP | disclosed |
| EP-2021333-B1 | ANTI-PROLIFERATIVE COMPOUNDS DERIVING FROM A 3-ARYL-COUMARINE OR 3-ARYL-QUINOLIN-2-ONE AND USES THEREOF | EOS ETHICAL ONCOLOGY SCIENCE S (IT) | 2010-07-14 | — | — | EP | disclosed |
| US-20090203685-A1 | ANTI-PROLIFERATIVE COMPOUNDS FROM A 3-ARYL-COUMARINE OR 3-ARYL-QUINOLIN-2-ONE AND USES THEREOF | EOS (ETHICAL ONCOLOGY SCIENCE) S.P.A. (IT) | 2009-08-13 | — | — | US | disclosed |
| US-20090203685-A1 | ANTI-PROLIFERATIVE COMPOUNDS FROM A 3-ARYL-COUMARINE OR 3-ARYL-QUINOLIN-2-ONE AND USES THEREOF | EOS (ETHICAL ONCOLOGY SCIENCE) S.P.A. (IT) | 2009-08-13 | — | — | US | disclosed |
| US-20090203685-A1 | ANTI-PROLIFERATIVE COMPOUNDS FROM A 3-ARYL-COUMARINE OR 3-ARYL-QUINOLIN-2-ONE AND USES THEREOF | EOS (ETHICAL ONCOLOGY SCIENCE) S.P.A. (IT) | 2009-08-13 | — | — | US | disclosed |
| EP-2021333-A2 | ANTI-PROLIFERATIVE COMPOUNDS DERIVING FROM A 3-ARYL-COUMARINE OR 3-ARYL-QUINOLIN-2-ONE AND USES THEREOF | EOS - Ethical Oncology Science S.p.A. (IT) | 2009-02-11 | — | — | EP | disclosed |
| WO-2007135565-A2 | ANTI-PROLIFERATIVE COMPOUNDS DERIVING FROM A 3-ARYL-COUMARINE OR 3-ARYL-QUINOLIN-2-ONE AND USES THEREOF | EOS (ETHICAL ONCOLOGY SCIENCE) S.P.A. (IT) | 2007-11-29 | — | — | WO | disclosed |
| WO-2007135565-A2 | ANTI-PROLIFERATIVE COMPOUNDS DERIVING FROM A 3-ARYL-COUMARINE OR 3-ARYL-QUINOLIN-2-ONE AND USES THEREOF | EOS (ETHICAL ONCOLOGY SCIENCE) S.P.A. (IT) | 2007-11-29 | — | — | WO | disclosed |
| EP-1860104-A1 | Anti-proliferative compounds deriving from a 3-aryl-coumarine or 3-aryl-quinolin-2-one and uses thereof | Aptanomics (FR) | 2007-11-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203685-A1 | ANTI-PROLIFERATIVE COMPOUNDS FROM A 3-ARYL-COUMARINE OR 3-ARYL-QUINOLIN-2-ONE AND USES THEREOF | MKI67, CCNA1, CCNI | ALDH1A1 376/4885MAPT 4821/4885KDM4E 1350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.